{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T02:03:43Z","timestamp":1761789823518,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current influenza vaccines have a suboptimal effectiveness. The introduction of a novel A\/H1N1 influenza virus in 2009 (H1N1pdm09) provided a unique opportunity to study the humoral response to the AS03-adjuvanted H1N1pdm09 vaccine and repeated annual vaccination with the homologous virus in subsequent influenza seasons. Thirty-two HCWs immunized with the AS03-adjuvanted H1N1pdm09 vaccine in 2009 were divided into four groups based on the longevity of their antibody responses (persistently high or transient), and whether they were repeatedly annually vaccinated in the subsequent four influenza seasons or not. Serological assays were utilized to measure the quantity, quality and functionality of antibodies targeting the major surface glycoprotein hemagglutinin (HA). Persistent high responders (hemagglutination inhibition (HI) titre\u2009\u2265\u200980 at 12 months after H1N1pdm09 vaccination) had protective levels of HI antibodies throughout the study period. In addition, the quality and functionality of these antibodies were greater than the individuals who had a transient antibody response to the pandemic vaccine (HI titre\u2009&lt;\u200940 at 12 months after H1N1pdm09 vaccination). All groups had similar levels of antibodies towards the conserved HA stalk domain. The level of HA head-specific antibodies gradually increased over time with annual vaccination in the transient responders. The AS03-adjuvanted H1N1pdm09 vaccine elicited a robust humoral response that persisted up to 5 years in some individuals. Seasonal annual vaccination boosted the HA-antibodies over time in individuals with a transient response to the pandemic H1N1pdm09 vaccine.<\/jats:p>","DOI":"10.1038\/s41541-021-00308-5","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T10:03:08Z","timestamp":1617271388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response"],"prefix":"10.1038","volume":"6","author":[{"given":"Anders","family":"Madsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c5sne","family":"Jul-Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai-Chi","family":"Trieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-4078","authenticated-orcid":false,"given":"Rebecca J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"308_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285\u20131300 (2018).","journal-title":"Lancet"},{"key":"308_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/infdis\/jiy633","volume":"219","author":"CI Paules","year":"2019","unstructured":"Paules, C. I. & Fauci, A. S. Influenza vaccines: good, but we can do better. J. Infect. Dis. 219, S1\u2013S4 (2019).","journal-title":"J. Infect. Dis."},{"key":"308_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"YQ Chen","year":"2018","unstructured":"Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417\u2013429.e410 (2018).","journal-title":"Cell"},{"key":"308_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fimmu.2012.00053","volume":"3","author":"AH Ellebedy","year":"2012","unstructured":"Ellebedy, A. H. & Ahmed, R. Re-engaging cross-reactive memory B cells: the influenza puzzle. Front. Immunol. 3, 53 (2012).","journal-title":"Front. Immunol."},{"key":"308_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"308_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4049\/jimmunol.1801054","volume":"202","author":"LD Estrada","year":"2019","unstructured":"Estrada, L. D. & Schultz-Cherry, S. Development of a universal influenza vaccine. J. Immunol. 202, 392\u2013398 (2019).","journal-title":"J. Immunol."},{"key":"308_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","volume":"3","author":"F Krammer","year":"2013","unstructured":"Krammer, F. & Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3, 521\u2013530 (2013).","journal-title":"Curr. Opin. Virol."},{"key":"308_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Investig. 126, 605\u2013610 (2016).","journal-title":"J. Clin. Investig."},{"key":"308_CR9","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","volume":"29","author":"S Morel","year":"2011","unstructured":"Morel, S. et al. Adjuvant System AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29, 2461\u20132473 (2011).","journal-title":"Vaccine"},{"key":"308_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/cid\/ciy487","volume":"68","author":"M-C Trieu","year":"2019","unstructured":"Trieu, M.-C. et al. Antibody responses to influenza A\/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: a 5-year follow-up study. Clin. Infect. Dis. 68, 382\u2013392 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"308_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.vaccine.2010.10.038","volume":"29","author":"AS Madhun","year":"2010","unstructured":"Madhun, A. S. et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 29, 266\u2013273 (2010).","journal-title":"Vaccine"},{"key":"308_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1017\/S0022172400022610","volume":"70","author":"D Hobson","year":"1972","unstructured":"Hobson, D., Curry, R., Beare, A. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Epidemiol. Infect. 70, 767\u2013777 (1972).","journal-title":"Epidemiol. Infect."},{"key":"308_CR13","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1128\/JCM.00229-11","volume":"49","author":"V Veguilla","year":"2011","unstructured":"Veguilla, V. et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in US populations. J. Clin. Microbiol. 49, 2210\u20132215 (2011).","journal-title":"J. Clin. Microbiol."},{"key":"308_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/erv.11.192","volume":"11","author":"N Gar\u00e7on","year":"2012","unstructured":"Gar\u00e7on, N., Vaughn, D. W. & Didierlaurent, A. M. Development and evaluation of AS03, an Adjuvant System containing \u03b1-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. vaccines 11, 349\u2013366 (2012).","journal-title":"Expert Rev. vaccines"},{"key":"308_CR15","doi-asserted-by":"publisher","first-page":"e00553","DOI":"10.1128\/CVI.00553-16","volume":"24","author":"RG van der Most","year":"2017","unstructured":"van der Most, R. G. et al. Long-Term Persistence of Cell-Mediated and Humoral Responses to A (H1N1) pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials. Clin. Vaccine Immunol. 24, e00553\u201316 (2017).","journal-title":"Clin. Vaccine Immunol."},{"key":"308_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep37229","volume":"6","author":"J Galson","year":"2016","unstructured":"Galson, J., Tr\u00fcck, J., Kelly, D. & Van der Most, R. Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination. Sci. Rep. 6, 37229 (2016).","journal-title":"Sci. Rep."},{"key":"308_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2711-0","volume":"586","author":"JS Turner","year":"2020","unstructured":"Turner, J. S. et al. Human germinal centres engage memory and naive B cells after influenza vaccination. Nature 586, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"308_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nm.2262","volume":"17","author":"AC Monsalvo","year":"2011","unstructured":"Monsalvo, A. C. et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat. Med. 17, 195\u2013199 (2011).","journal-title":"Nat. Med."},{"key":"308_CR19","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1016\/j.vaccine.2015.05.081","volume":"33","author":"S Eidem","year":"2015","unstructured":"Eidem, S. et al. Persistence and avidity maturation of antibodies to A (H1N1) pdm09 in healthcare workers following repeated annual vaccinations. Vaccine 33, 4146\u20134154 (2015).","journal-title":"Vaccine"},{"key":"308_CR20","first-page":"740","volume":"215","author":"M-C Trieu","year":"2017","unstructured":"Trieu, M.-C. et al. Long-term maintenance of the influenza-specific cross-reactive memory CD4+T-cell responses following repeated annual influenza vaccination. J. Infect. Dis. 215, 740\u2013749 (2017).","journal-title":"J. Infect. Dis."},{"key":"308_CR21","doi-asserted-by":"crossref","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. 81, e51112 (2013).","DOI":"10.3791\/51112"},{"key":"308_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","volume":"37","author":"T Rowe","year":"1999","unstructured":"Rowe, T. et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37, 937\u2013943 (1999).","journal-title":"J. Clin. Microbiol."},{"key":"308_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjvaccines.2016.1","volume":"1","author":"SM Tete","year":"2016","unstructured":"Tete, S. M. et al. Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination. npj Vaccines 1, 1\u20139 (2016).","journal-title":"npj Vaccines"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00308-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:30:37Z","timestamp":1670023837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00308-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["308"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00308-5","relation":{},"ISSN":["2059-0105"],"issn-type":[{"type":"electronic","value":"2059-0105"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"10 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}